Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -31.5%
- Operating Margin Trend +3914.47 pp/yr
VERV
Verve Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 25.5 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -33.9%
- 5yr Share-Count CAGR 23.8%
Growth Quality
Weight: 35%
D+
40
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -2944.8%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
D+
41
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 2.08
Stability
Weight: 5%
C+
58
- Negative-Revenue Years (5) 0/5
- Piotroski F-Score 2
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 new buy.
- Holders
- 1 -1
- Avg Δ position
- —
- New buys
- 1
- Full exits
- 0
- Cooperman new